The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment.

Angiogenesis is a key step in the pathophysiology of tumor growth and metastatic spread. Recently, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has emerged as a method for assessing angiogenesis both during the initial diagnosis and for follow up of anti-angiogenic therapies. In this review, we discuss the technical aspects of implementing DCE-MRI in clinical practice with emphasis on acquisition methods and analytic techniques.

[1]  M. Knopp,et al.  Functional tumor imaging with dynamic contrast‐enhanced magnetic resonance imaging , 2003, Journal of magnetic resonance imaging : JMRI.

[2]  Walter H Backes,et al.  Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. , 2005, Radiology.

[3]  A. Padhani,et al.  Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging , 2005, Abdominal Imaging.

[4]  G Brix,et al.  Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. , 2001, Cancer research.

[5]  W Zhen,et al.  Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer , 2000, Journal of magnetic resonance imaging : JMRI.

[6]  A. Padhani,et al.  Assessing changes in tumour vascular function using dynamic contrast‐enhanced magnetic resonance imaging , 2002, NMR in biomedicine.

[7]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[8]  N. Kosaka,et al.  Assessment of the Vascularity of Uterine Leiomyomas Using Double-Echo Dynamic Perfusion-Weighted MRI With the First-Pass Pharmacokinetic Model: Correlation With Histopathology , 2007, Investigative radiology.

[9]  J. Witjes,et al.  Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. , 1998, Radiology.

[10]  W E Reddick,et al.  Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma , 1999, Journal of magnetic resonance imaging : JMRI.

[11]  M.-Y.L. Su.  Inflammatory Breast Cancer: Dynamic Contrast-enhanced MR in Patients Receiving Bevacizumab—Initial Experience , 2008 .

[12]  H Baddeley,et al.  Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. , 1999, The British journal of radiology.

[13]  Kevin Camphausen,et al.  Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J R Thornbury,et al.  Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. , 1997, Radiology.

[15]  Tristan Barrett,et al.  Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. , 2007, AJR. American journal of roentgenology.

[16]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[17]  P.-F. Liu,et al.  MRI of the uterus, uterine cervix, and vagina: diagnostic performance of dynamic contrast-enhanced fast multiplanar gradient-echo imaging in comparison with fast spin-echo T2-weighted pulse imaging , 1998, European Radiology.